Format

Send to

Choose Destination
J Clin Anesth. 1994 Nov-Dec;6(6):515-20.

Administration of high-dose aprotinin during nonprimary cardiovascular surgery: case reports and review of the literature.

Author information

1
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas 75235-9068.

Abstract

The perioperative management of two patients undergoing complex "redo" cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a "compassionate use" protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.

PMID:
7533505
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center